FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2941129539> ?p ?o ?g. }

• W2941129539 abstract "Abstract HER3 is the third member of the human epidermal growth factor receptor (HER/EGFR) family, and unlike its other family members, is unique due to its minimal intrinsic kinase activity. As a result, HER3 has to interact with another receptor tyrosine kinase (RTK), such as EGFR or HER2, in order to activate the PI-3 K/Akt, MEK/MAPK, Jak/Stat pathways, as well as Src kinase. Over-expression of HER3 in various human cancers promotes tumor progression by increasing metastatic potential and acting as a major cause of treatment failure. Effective inhibition of HER3, and/or the key downstream mediators of HER3 signaling, is thought to be required to overcome resistance and enhance therapeutic efficacy. To date, there is no known HER3-targeted therapy that is approved for breast cancer, with a number of anti-HER3 antibodies current in various stages of development and clinical testing. Recent data suggests that the epigenetic strategy of using a histone deacetylase (HDAC) inhibitor, or functional cooperative miRNAs, may be an effective way to abrogate HER3 signaling. Here, we summarize the latest advances in our understanding of the mechanism of HER3 signaling in tumor progression, with continuing research towards the identification of therapeutic anti-HER3 antibodies. We will also examine the potential to develop novel epigenetic approaches that specifically target the HER3 receptor, along with important key downstream mediators that are involved in cancer treatment." @default.
• W2941129539 created "2019-05-03" @default.
• W2941129539 creator A5000979147 @default.
• W2941129539 creator A5033456528 @default.
• W2941129539 creator A5047737377 @default.
• W2941129539 creator A5048727442 @default.
• W2941129539 creator A5061223537 @default.
• W2941129539 creator A5087841432 @default.
• W2941129539 date "2019-03-19" @default.
• W2941129539 modified "2023-10-12" @default.
• W2941129539 title "Development of Effective Therapeutics Targeting HER3 for Cancer Treatment" @default.
• W2941129539 cites W1514463309 @default.
• W2941129539 cites W1524668302 @default.
• W2941129539 cites W1531854417 @default.
• W2941129539 cites W1537035141 @default.
• W2941129539 cites W1578523240 @default.
• W2941129539 cites W1589166971 @default.
• W2941129539 cites W1797430954 @default.
• W2941129539 cites W1870193477 @default.
• W2941129539 cites W1893360284 @default.
• W2941129539 cites W1965864591 @default.
• W2941129539 cites W1967920636 @default.
• W2941129539 cites W1973144992 @default.
• W2941129539 cites W1973555911 @default.
• W2941129539 cites W1978025728 @default.
• W2941129539 cites W1978916359 @default.
• W2941129539 cites W1979056373 @default.
• W2941129539 cites W1984469163 @default.
• W2941129539 cites W1985620074 @default.
• W2941129539 cites W1993804787 @default.
• W2941129539 cites W1997663906 @default.
• W2941129539 cites W1998232305 @default.
• W2941129539 cites W1998549015 @default.
• W2941129539 cites W1998971866 @default.
• W2941129539 cites W2001447115 @default.
• W2941129539 cites W2002796256 @default.
• W2941129539 cites W2009031388 @default.
• W2941129539 cites W2010662888 @default.
• W2941129539 cites W2012612761 @default.
• W2941129539 cites W2012915718 @default.
• W2941129539 cites W2014457594 @default.
• W2941129539 cites W2017081079 @default.
• W2941129539 cites W2017290745 @default.
• W2941129539 cites W2018204057 @default.
• W2941129539 cites W2028465494 @default.
• W2941129539 cites W2033488181 @default.
• W2941129539 cites W2038846160 @default.
• W2941129539 cites W2041919461 @default.
• W2941129539 cites W2043879899 @default.
• W2941129539 cites W2045075564 @default.
• W2941129539 cites W2045228008 @default.
• W2941129539 cites W2048209624 @default.
• W2941129539 cites W2049610624 @default.
• W2941129539 cites W2052812818 @default.
• W2941129539 cites W2053301892 @default.
• W2941129539 cites W2058620780 @default.
• W2941129539 cites W2066081464 @default.
• W2941129539 cites W2069526613 @default.
• W2941129539 cites W2070842899 @default.
• W2941129539 cites W2078374613 @default.
• W2941129539 cites W2087865412 @default.
• W2941129539 cites W2088356680 @default.
• W2941129539 cites W2090855460 @default.
• W2941129539 cites W2096878683 @default.
• W2941129539 cites W2098158231 @default.
• W2941129539 cites W2098210795 @default.
• W2941129539 cites W2098544382 @default.
• W2941129539 cites W2102627944 @default.
• W2941129539 cites W2103576580 @default.
• W2941129539 cites W2105426251 @default.
• W2941129539 cites W2106567943 @default.
• W2941129539 cites W2107846614 @default.
• W2941129539 cites W2110933411 @default.
• W2941129539 cites W2112853929 @default.
• W2941129539 cites W2116025464 @default.
• W2941129539 cites W2118221532 @default.
• W2941129539 cites W2120213327 @default.
• W2941129539 cites W2123206362 @default.
• W2941129539 cites W2125947965 @default.
• W2941129539 cites W2126022125 @default.
• W2941129539 cites W2137672355 @default.
• W2941129539 cites W2139444209 @default.
• W2941129539 cites W2143600397 @default.
• W2941129539 cites W2145451310 @default.
• W2941129539 cites W2147767711 @default.
• W2941129539 cites W2148267549 @default.
• W2941129539 cites W2149456035 @default.
• W2941129539 cites W2151464858 @default.
• W2941129539 cites W2152095899 @default.
• W2941129539 cites W2152163220 @default.
• W2941129539 cites W2154608911 @default.
• W2941129539 cites W2156214225 @default.
• W2941129539 cites W2158819778 @default.
• W2941129539 cites W2158859033 @default.
• W2941129539 cites W2160574552 @default.
• W2941129539 cites W2161959295 @default.
• W2941129539 cites W2168534525 @default.
• W2941129539 cites W2169279258 @default.
• W2941129539 cites W2178676862 @default.
• W2941129539 cites W2194026923 @default.

• next